An Investigation of Psilocybin on Behavioural and Cognitive Symptoms of Adults With Fragile X Syndrome
Status:
Recruiting
Trial end date:
2023-08-01
Target enrollment:
Participant gender:
Summary
Diverse symptomatology makes Fragile X Syndrome (FXS) difficult to treat, and currently there
are no approved prevention or treatment methods for FXS. Current therapies, including
pharmaceutical and behavioural interventions, offer a patchwork of solutions that have
limited efficacy and high toxicity. The current study aims to examine psilocybin as a safe
treatment alternative with the ability to improve markers of cognition, communication, mood,
behavior as well as markers of neuroinflammation, serotonin levels in exosomes, and
neuroplasticity at sub-hallucinogenic doses (microdosing).
The overall objective of this study is to assess the feasibility of low-dose psilocybin as a
therapeutic option for individuals living with FXS and to improve diagnostic parameters of
FXS, as well as therapeutic responses with the use of biomarkers.